Skip to main content
SpringerLink
Log in

Immunohistochemical screening for mismatch repair protein deficiency in paediatric high-grade gliomas — institutional experience and review of literature

  • Original Article
  • Published:
Child's Nervous System Aims and scope Submit manuscript

Abstract

Purpose

Immunohistochemical (IHC) testing for mismatch repair (MMR) deficiency (MMRD) is used as a screening tool to identify microsatellite instability in various cancers (especially colon). This not only identifies hereditary cancer syndromes like Lynch and constitutional mismatch repair deficiency (CMMRD) but also aids in prognostication and prediction of sensitivity to checkpoint inhibitor drugs. There are very few reported studies on MMRD status of pediatric high-grade gliomas (pHGG) and none from the Indian subcontinent. The aim of this study is to evaluate the frequency of MMRD in pHGG and to assess if there is a need for universal screening with immunohistochemistry.

Methods

Paraffin blocks of consecutive cases of pHGG (< 18 years) were retrieved from 2 centres, and IHC with four MMR antibodies — MLH1, PMS2, MSH2 and MSH6 — was performed using tissue microarray-based technique.

Results

Three out of nine cases (33%) studied showed loss of staining. One case had loss of MSH2 and MSH6 confirmed by gene sequencing. Eight of the cases were glioblastoma. One case of IDH1-mutated anaplastic astrocytoma showed loss of MLH1 and PMS2 staining. Isolated PMS2 loss was noted in 1 case, where the non-tumour cells also showed loss of staining, indicative CMMRD syndrome. This patient had prior colon cancer with isolated PMS2 loss and responded to check-point inhibitor therapy with nivolumab.

Conclusion

Our study shows that the frequency of MMRD to be about one-third of pHGG. Universal IHC screening for MMRD in all pHGGs may benefit early diagnosis and play a role in therapeutic decisions. A larger multi-institutional study will help better assess the prevalence and treatment implications in MMRD tumours.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Availability of data and material

Available.

References

  1. Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, Miller R, Riaz N, Douillard JY, Andre F, Scarpa A (2019) ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol 30:1232–1243

    Article  CAS  Google Scholar 

  2. Yang C, Austin F, Richard H, Idowu M, Williamson V, Sabato F, Ferreira-Gonzalez A, Turner SA (2019) Lynch syndrome-associated ultra-hypermutated pediatric glioblastoma mimicking a constitutional mismatch repair deficiency syndrome. Cold Spring Harb Mol Case Stud 5

  3. Kohlmann W, Gruber SB (1993) Lynch Syndrome. In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A (eds) GeneReviews((R)), Seattle (WA)

  4. Poley JW, Wagner A, Hoogmans MM, Menko FH, Tops C, Kros JM, Reddingius RE, Meijers-Heijboer H, Kuipers EJ, Dinjens WN (2007) Rotterdam Initiative on Gastrointestinal Hereditary Tumors. Biallelic germline mutations of mismatch-repair genes: a possible cause for multiple pediatric malignancies. Cancer 109:2349–2356

    Article  Google Scholar 

  5. Blionas A, Giakoumettis D, Klonou A, Neromyliotis E, Karydakis P, Themistocleous MS (2018) Paediatric gliomas: diagnosis, molecular biology and management. Ann Transl Med 6:251

    Article  Google Scholar 

  6. Galuppini F, Opocher E, Tabori U, Mammi I, Edwards M, Campbell B, Kelly J, Viel A, Quaia M, Rivieri F, D’Avella D, Arcella A, Giangaspero F, Fassan M, Gardiman MP (2018) Concomitant IDH wild-type glioblastoma and IDH1-mutant anaplastic astrocytoma in a patient with constitutional mismatch repair deficiency syndrome. Neuropathol Appl Neurobiol 44:233–239

    Article  CAS  Google Scholar 

  7. Guerrini-Rousseau L, Varlet P, Colas C, Andreiuolo F, Bourdeaut F, Dahan K, Devalck C, Faure-Conter C, Genuardi M, Goldberg Y, Kuhlen M, Moalla S, Opocher E, Perez-Alonso V, Sehested A, Slavc I, Unger S, Wimmer K, Grill J, Brugières L (2019) Constitutional mismatch repair deficiency-associated brain tumors: report from the European C4CMMRD consortium. Neurooncol Adv 1:vdz033

  8. Eckert A, Kloor M, Giersch A, Ahmadi R, Herold-Mende C, Hampl JA, Heppner FL, Zoubaa S, Holinski-Feder E, Pietsch T, Wiestler OD, von Knebel DM, Roth W, Gebert J (2007) Microsatellite instability in pediatric and adult high-grade gliomas. Brain Pathol 17:146–150

    Article  CAS  Google Scholar 

  9. Cheng Y, Ng HK, Zhang SF, Ding M, Pang JC, Zheng J, Poon WS (1999) Genetic alterations in pediatric high-grade astrocytomas. Hum Pathol 30:1284–1290

    Article  CAS  Google Scholar 

  10. Alonso M, Hamelin R, Kim M, Porwancher K, Sung T, Parhar P, Miller DC, Newcomb EW (2001) Microsatellite instability occurs in distinct subtypes of pediatric but not adult central nervous system tumors. Cancer Res 61:2124–2128

    CAS  PubMed  Google Scholar 

  11. Kanamori M, Kon H, Nobukuni T, Nomura S, Sugano K, Mashiyama S, Kumabe T, Yoshimoto T, Meuth M, Sekiya T, Murakami Y (2000) Microsatellite instability and the PTEN1 gene mutation in a subset of early onset gliomas carrying germline mutation or promoter methylation of the hMLH1 gene. Oncogene 19:1564–1571

    Article  CAS  Google Scholar 

  12. Bouffet E, Larouche V, Campbell BB, Merico D, de Borja R, Aronson M, Durno C, Krueger J, Cabric V, Ramaswamy V, Zhukova N, Mason G, Farah R, Afzal S, Yalon M, Rechavi G, Magimairajan V, Walsh MF, Constantini S, Dvir R, Elhasid R, Reddy A, Osborn M, Sullivan M, Hansford J, Dodgshun A, Klauber-Demore N, Peterson L, Patel S, Lindhorst S, Atkinson J, Cohen Z, Laframboise R, Dirks P, Taylor M, Malkin D, Albrecht S, Dudley RW, Jabado N, Hawkins CE, Shlien A, Tabori U (2016) Immune checkpoint inhibition for hypermutant glioblastoma multiforme resulting from germline biallelic mismatch repair deficiency. J Clin Oncol 34:2206–2211

    Article  CAS  Google Scholar 

  13. Amayiri N, Tabori U, Campbell B, Bakry D, Aronson M, Durno C, Rakopoulos P, Malkin D, Qaddoumi I, Musharbash A, Swaidan M, Bouffet E, Hawkins C, Al-Hussaini M, Consortium B (2016) High frequency of mismatch repair deficiency among pediatric high grade gliomas in Jordan. Int J Cancer 138:380–385

    Article  CAS  Google Scholar 

  14. Giunti L, Cetica V, Ricci U, Giglio S, Sardi I, Paglierani M, Andreucci E, Sanzo M, Forni M, Buccoliero AM, Genitori L, Genuardi M (2009) Type A microsatellite instability in pediatric gliomas as an indicator of Turcot syndrome. Eur J Hum Genet 17:919–927

    Article  CAS  Google Scholar 

  15. Szybka M, Bartkowiak J, Zakrzewski K, Polis L, Liberski P, Kordek R (2003) Microsatellite instability and expression of DNA mismatch repair genes in malignant astrocytic tumors from adult and pediatric patients. Clin Neuropathol 22:180–186

    CAS  PubMed  Google Scholar 

  16. Viana-Pereira M, Lee A, Popov S, Bax DA, Al-Sarraj S, Bridges LR, Stavale JN, Hargrave D, Jones C, Reis RM (2011) Microsatellite instability in pediatric high grade glioma is associated with genomic profile and differential target gene inactivation. PLoS One 6:e20588

    Article  CAS  Google Scholar 

  17. Kebudi R, Amayiri N, Abedalthagafi M, Rana AN, Kirmani S, Musthaq N, Lamki ZA, Houdzi JE, Yazici H, El-Naggar S, Edwards M, Bianchi VJ, Durno C, Tabori U, Bouffet E, International RRDCoL-RSP (2020) Position paper: challenges and specific strategies for constitutional mismatch repair deficiency syndrome in low-resource settings. Pediatr Blood Cancer 67(8):e28309

  18. Pollack IF, Hamilton RL, Sobol RW, Nikiforova MN, Nikiforov YE, Lyons-Weiler MA, LaFramboise WA, Burger PC, Brat DJ, Rosenblum MK, Gilles FH, Yates AJ, Zhou T, Cohen KJ, Finlay JL, Jakacki RI, Children’s Oncology G (2010) Mismatch repair deficiency is an uncommon mechanism of alkylator resistance in pediatric malignant gliomas: a report from the Children’s Oncology Group. Pediatr Blood Cancer 55:1066–1071

    Article  Google Scholar 

  19. Vladimirova V, Denkhaus D, Soerensen N, Wagner S, Wolff JE, Pietsch T (2008) Low level of microsatellite instability in paediatric malignant astrocytomas. Neuropathol Appl Neurobiol 34:547–554

    Article  CAS  Google Scholar 

  20. Almuhaisen G, Alhalaseh Y, Mansour R, Abu-Shanab A, Al-Ghnimat S, Al-Hussaini M (2020) Frequency of mismatch repair protein deficiency and PD-L1 in high-grade gliomas in adolescents and young adults (AYA). Brain Tumor Pathol

  21. Nayak SS, Roy P, Arora N, Arun I, Roy MK, Banerjee S, Mallick I, Mallath MK (2018) Prevalence estimation of microsatellite instability in colorectal cancers using tissue microarray based methods - a tertiary care center experience. Indian J Pathol Microbiol 61:520–525

    Article  Google Scholar 

  22. Martinez R, Schackert HK, Appelt H, Plaschke J, Baretton G, Schackert G (2005) Low-level microsatellite instability phenotype in sporadic glioblastoma multiforme. J Cancer Res Clin Oncol 131:87–93

    Article  CAS  Google Scholar 

  23. Touat M, Li YY, Boynton AN, Spurr LF, Iorgulescu JB, Bohrson CL, Cortes-Ciriano I, Birzu C, Geduldig JE, Pelton K, Lim-Fat MJ, Pal S, Ferrer-Luna R, Ramkissoon SH, Dubois F, Bellamy C, Currimjee N, Bonardi J, Qian K, Ho P, Malinowski S, Taquet L, Jones RE, Shetty A, Chow KH, Sharaf R, Pavlick D, Albacker LA, Younan N, Baldini C, Verreault M, Giry M, Guillerm E, Ammari S, Beuvon F, Mokhtari K, Alentorn A, Dehais C, Houillier C, Laigle-Donadey F, Psimaras D, Lee EQ, Nayak L, McFaline-Figueroa JR, Carpentier A, Cornu P, Capelle L, Mathon B, Barnholtz-Sloan JS, Chakravarti A, Bi WL, Chiocca EA, Fehnel KP, Alexandrescu S, Chi SN, Haas-Kogan D, Batchelor TT, Frampton GM, Alexander BM, Huang RY, Ligon AH, Coulet F, Delattre JY, Hoang-Xuan K, Meredith DM, Santagata S, Duval A, Sanson M, Cherniack AD, Wen PY, Reardon DA, Marabelle A, Park PJ, Idbaih A, Beroukhim R, Bandopadhayay P, Bielle F, Ligon KL (2020) Mechanisms and therapeutic implications of hypermutation in gliomas. Nature 580:517–523

    Article  CAS  Google Scholar 

  24. Gylling AH, Nieminen TT, Abdel-Rahman WM, Nuorva K, Juhola M, Joensuu EI, Jarvinen HJ, Mecklin JP, Aarnio M, Peltomaki PT (2008) Differential cancer predisposition in Lynch syndrome: insights from molecular analysis of brain and urinary tract tumors. Carcinogenesis 29:1351–1359

    Article  CAS  Google Scholar 

  25. Braunstein S, Raleigh D, Bindra R, Mueller S, Haas-Kogan D (2017) Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. J Neurooncol 134:541–549

    Article  CAS  Google Scholar 

  26. Lavoine N, Colas C, Muleris M, Bodo S, Duval A, Entz-Werle N, Coulet F, Cabaret O, Andreiuolo F, Charpy C, Sebille G, Wang Q, Lejeune S, Buisine MP, Leroux D, Couillault G, Leverger G, Fricker JP, Guimbaud R, Mathieu-Dramard M, Jedraszak G, Cohen-Hagenauer O, Guerrini-Rousseau L, Bourdeaut F, Grill J, Caron O, Baert-Dusermont S, Tinat J, Bougeard G, Frebourg T, Brugieres L (2015) Constitutional mismatch repair deficiency syndrome: clinical description in a French cohort. J Med Genet 52:770–778

    Article  CAS  Google Scholar 

  27. Therkildsen C, Ladelund S, Rambech E, Persson A, Petersen A, Nilbert M (2015) Glioblastomas, astrocytomas and oligodendrogliomas linked to Lynch syndrome. Eur J Neurol 22:717–724

    Article  CAS  Google Scholar 

  28. Wimmer K, Kratz CP, Vasen HF, Caron O, Colas C, Entz-Werle N, Gerdes AM, Goldberg Y, Ilencikova D, Muleris M, Duval A, Lavoine N, Ruiz-Ponte C, Slavc I, Burkhardt B, Brugieres L, CMMRD EU-CCf, (2014) Diagnostic criteria for constitutional mismatch repair deficiency syndrome: suggestions of the European consortium “care for CMMRD” (C4CMMRD). J Med Genet 51:355–365

    Article  CAS  Google Scholar 

  29. Xie C, Sheng H, Zhang N, Li S, Wei X, Zheng X (2016) Association of MSH6 mutation with glioma susceptibility, drug resistance and progression. Mol Clin Oncol 5:236–240

    Article  CAS  Google Scholar 

  30. Abedalthagafi M (2018) Constitutional mismatch repair-deficiency: current problems and emerging therapeutic strategies. Oncotarget 9:35458–35469

    Article  Google Scholar 

  31. Farah RA, Maalouf F, Chahine NA, Farhat H, Campbell B, Zhukova N, Durno C, Aronson M, Hawkins C, Bouffet E, Tabori U (2019) Ongoing issues with the management of children with constitutional mismatch repair deficiency syndrome. Eur J Med Genet 62:103706

    Article  Google Scholar 

  32. Tabori U, Hansford JR, Achatz MI, Kratz CP, Plon SE, Frebourg T, Brugieres L (2017) Clinical management and tumor surveillance recommendations of inherited mismatch repair deficiency in childhood. Clin Cancer Res 23:e32–e37

    Article  Google Scholar 

  33. Rodriguez-Hernandez I, Garcia JL, Santos-Briz A, Hernandez-Lain A, Gonzalez-Valero JM, Gomez-Moreta JA, Toldos-Gonzalez O, Cruz JJ, Martin-Vallejo J, Gonzalez-Sarmiento R (2013) Integrated analysis of mismatch repair system in malignant astrocytomas. PLoS One 8:e76401

    Article  CAS  Google Scholar 

  34. Stark AM, Doukas A, Hugo HH, Mehdorn HM (2010) The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma. Neurol Res 32:816–820

    Article  Google Scholar 

  35. Tepeoglu M, Borcek P, Ozen O, Altinors N (2019) Microsatellite instability in glioblastoma: is it really relevant in tumor prognosis? Turk Neurosurg 29:778–784

    PubMed  Google Scholar 

  36. Pollack IF, Hamilton RL, Sobol RW, Burnham J, Yates AJ, Holmes EJ, Zhou T, Finlay JL (2006) O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol 24:3431–3437

    Article  CAS  Google Scholar 

  37. Yip S, Miao J, Cahill DP, Iafrate AJ, Aldape K, Nutt CL, Louis DN (2009) MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. Clin Cancer Res 15:4622–4629

    Article  CAS  Google Scholar 

  38. Kline C, Felton E, Allen IE, Tahir P, Mueller S (2018) Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis. J Neurooncol 137:103–110

    Article  Google Scholar 

  39. AlHarbi M, Ali Mobark N, AlMubarak L, Aljelaify R, AlSaeed M, Almutairi A, Alqubaishi F, Hussain ME, Balbaid AAO, Marie AS, AlSubaie L, AlShieban S, alTassan N, Ramkissoon SH, Abedalthagafi M (2018) Durable response to nivolumab in a pediatric patient with refractory glioblastoma and constitutional biallelic mismatch repair deficiency. Oncologist 23:1401–1406

    Article  CAS  Google Scholar 

  40. Medikonda R, Dunn G, Rahman M, Fecci P, Lim M (2021) A review of glioblastoma immunotherapy. J Neurooncol 151(1):41–53

  41. Chang L, Chang M, Chang HM, Chang F (2018) Microsatellite instability: a predictive biomarker for cancer immunotherapy. Appl Immunohistochem Mol Morphol 26:e15–e21

    Article  CAS  Google Scholar 

  42. Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, Reddy SK, Spetzler D, Heimberger AB (2016) Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol 18:1357–1366

    Article  CAS  Google Scholar 

  43. Kline C, Liu SJ, Duriseti S, Banerjee A, Nicolaides T, Raber S, Gupta N, Haas-Kogan D, Braunstein S, Mueller S (2018) Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. J Neurooncol 140:629–638

    Article  CAS  Google Scholar 

  44. McGranahan T, Therkelsen KE, Ahmad S, Nagpal S (2019) Current state of immunotherapy for treatment of glioblastoma. Curr Treat Options Oncol 20:24

    Article  Google Scholar 

  45. Hwang K, Koh EJ, Choi EJ, Kang TH, Han JH, Choe G, Park SH, Yearley JH, Annamalai L, Blumenschein W, Sathe M, McClanahan T, Jung H, Wang KC, Kim SK, Kim CY (2018) PD-1/PD-L1 and immune-related gene expression pattern in pediatric malignant brain tumors: clinical correlation with survival data in Korean population. J Neurooncol 139:281–291

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank our technical staff (Mr Gopal Chakraborty — for his contribution to making the tissue microarray) and (Mr TK Giri — for his contribution to the IHC) done in this study.

Funding

Departmental funds were used for this study.

Author information

Authors and Affiliations

  1. Department of Pathology, Tata Medical Center, Kolkata, India

    Sheena Alphones, Angad Singh, Lateef Zameer & Paromita Roy

  2. Department of Pathology, Park Clinic, Kolkata, India

    Uttara Chatterjee

  3. Department of Pediatric Oncology, Tata Medical Center, Kolkata, India

    Anirban Das & Arpita Bhattacharya

  4. Department of Radiation Oncology, Tata Medical Center, Kolkata, India

    Rimpa Achari

Authors
  1. Sheena Alphones
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Uttara Chatterjee
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Angad Singh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Anirban Das
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lateef Zameer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Rimpa Achari
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Arpita Bhattacharya
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Paromita Roy
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Paromita Roy.

Ethics declarations

Ethics approval

Institutional review board approval (2019/TMC/166/IRB45) was taken, and all IRB mandated procedures for patient consent and publication consent were followed.

Conflict of interest

None.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Alphones, S., Chatterjee, U., Singh, A. et al. Immunohistochemical screening for mismatch repair protein deficiency in paediatric high-grade gliomas — institutional experience and review of literature. Childs Nerv Syst 37, 2521–2530 (2021). https://doi.org/10.1007/s00381-021-05229-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00381-021-05229-1

Keywords

Search

Navigation